Table 2.

Anti-cancer Drugs.

API Structure Loaded	Dendrimer Type (Formulation)	Effects/Results	References
Methotrexate	Triazine (G3)	Encapsulates 3 moles MTX per G3 dendrimer	[128,129]
Silybin	PEG-PAMAM (G4)	Encapsulation, high PEG increased solubility	[130]
Diferuloylmethane (curcumin)	FA-PAMAM	Encapsulation, increased solubility, targeted delivery	[131]
	HA-PAMAM	Encapsulation, increased cell uptake, reduced toxicity	[132]
	PAMAM-(3.5), (G4)	4.3–5.0 mol/dendrimer	[133]
	PAMAM-meso nanosilica	Encapsulation	[134]
Capecitabine	PAMAM-conjugated	Targeted delivery and lower toxicity	[135]
Paclitaxel	Poly(glycerol)	Encapsulation	[136]
	Triazine dendrimer-paclitaxel conjugates	Encapsulation	[137]
	PPI-(CO2H)	Encapsulation	[138]
	Antibody conjugate PAMAM-(NH2), (G4) lipid hybrid	×465-fold increased solubility and activity	[139]
	PAMAM poly(glycerol)(G4,5)	×400-fold increased solubility	[140]
Cisplatin	PAMAM-ester terminated	Solubility enhancement	[24,141]
	PPI-amino butyrate terminated		[142]
Tetramethylscutellarein	PAMAM-NH2, (G4)	Encapsulation Increased solubility	[143]
Camptothecin	PAMAM (NH2), (G5) PEGylated	Encapsulation Increased solubility	[144]
	Glycerol-succinic acid- poly(ester) dendrimer	×16-fold cell uptake	[73]
	PAMAM dendrimers	Encapsulation	[145]
Doxorubicin	PAMAM-(NH)2	Enhanced bioavailability	[146]
	PPI-NH2, dextrin conjugate	Enhanced solubility	[147]
	PPI-NH2, folate conjugated	Enhanced solubility	[148]
	PPI-NH2	6.5 drug/dendrimer	[114]
	PAMAM-(G4)PEG2000	91% encapsulated	[149]
	poly(ester); bowtie dendrimer architecture	Conjugated DOX yields Enhanced solubility	[150]
5-Flurouracil	PAMAM-NH2, G4	Encapsulation, high loading and	[151]
	PAMAM-CO2H, NH2	lower toxicity	[152]
	PAMAM-(G4)-PEG5000	×12-fold increased solubility	[153]
Berberine	PAMAM conjugation & encapsulation	Encapsulation, improved pharmacokinetics	[154]
Bendamustine	PAMAM-conjugation, G4	Improved stability/pharmacokinetics	[155]
Black carrot anthocyanin	PAMAM-mesoporous silica	Controlled release, lower toxicity, enhanced activity	[156]